Researchers Identify High-Risk Health Combination Linked to 83 Percent Higher Mortality

A collaborative study by Federal University of São Carlos and University College London has found that the combination of excess abdominal fat and low muscle mass significantly increases mortality risk. Individuals with both conditions were 83% more likely to die compared to those with neither risk factor.

This dangerous combination is known as Sarcopenic Obesity, a condition in which muscle mass declines while body fat increases. It is particularly common in older adults and is associated with reduced mobility, loss of independence, frailty, and a higher risk of falls and chronic health complications.

Researchers explain that excess fat contributes to chronic inflammation, which accelerates muscle breakdown. Fat can also infiltrate muscle tissue, further impairing its function. This process disrupts key metabolic, endocrine, and immune pathways, weakening the body’s overall physiological resilience. Over time, these changes can significantly affect quality of life and increase vulnerability to disease and death.

One major challenge in addressing sarcopenic obesity has been the lack of a standardized definition. To overcome this, the research team proposed simple, practical measures for early identification. Abdominal obesity was defined using waist circumference—greater than 102 cm in men and 88 cm in women—while low muscle mass was assessed using skeletal muscle mass index thresholds.

These accessible measurements could help clinicians identify at-risk individuals earlier without relying on complex or expensive diagnostic tools. Early detection is crucial, as targeted interventions such as resistance training, improved nutrition, and weight management strategies may help reverse or slow the progression of the condition.

The findings highlight the importance of not just monitoring body weight, but also assessing body composition. Addressing both fat accumulation and muscle loss is essential for improving long-term health outcomes and reducing mortality risk.

REFERENCE: Valdete Regina Guandalini, Patrícia Silva Tofani, Sara Souza Lima, Letícia Coelho Silveira, Natália Cochar-Soares, Thais Barros Pereira da Silva, Thales Batista de Souza, Mariane Marques Luiz, Paula Camila Ramírez, Roberta de Oliveira Máximo, Andrew Steptoe, Cesar de Oliveira, Tiago da Silva Alexandre. Can simple measures from clinical practice serve as a proxy for sarcopenic obesity and identify mortality risk? Aging Clinical and Experimental Research, 2024; 36 (1) DOI: 10.1007/s40520-024-02866-9